Iressa Survival Study Is Ahead Of Schedule; Tarceva Trial Is "Good News"
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca plans to meet with FDA and clinical investigators to discuss the progress of a lung cancer survival study of Iressa (gefitinib) once it sees the "details" of a study showing improved survival in patients treated with Genentech/OSI's Tarceva (erlotinib)
You may also be interested in...
Tarceva Price Will Be Bounded By Iressa And Gleevec, OSI Says
The dose and pharmacokinetic profile of Tarceva allow for premium pricing over AstraZeneca's Iressa, OSI CEO Colin Goddard says. Approval of Tarceva for the treatment of non-small cell lung cancer possible by late January.
Tarceva Price Will Be Bounded By Iressa And Gleevec, OSI Says
The dose and pharmacokinetic profile of Tarceva allow for premium pricing over AstraZeneca's Iressa, OSI CEO Colin Goddard says. Approval of Tarceva for the treatment of non-small cell lung cancer possible by late January.
Tarceva Monotherapy Shows Survival Benefit, Differentiates Oncologic From Iressa – Genentech
Genentech/OSI project summer filing and Q1 2005 launch following positive findings from a pivotal monotherapy study. The refractory NSCLC study is slated for presentation at the American Society of Clinical Oncology meeting in June.